Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 23Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 17Rectal Neoplasms 13Prostatic Neoplasms 13Gliosarcoma 12Lung Neoplasms 10Head and Neck Neoplasms 10Esophageal Neoplasms 10Brain Neoplasms 10Neoplasms 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Adenocarcinoma Of Esophagus 8Sarcoma 7Neoplasm Metastasis 7Central Nervous System Neoplasms 7Pancreatic Neoplasms 6Melanoma 6Glioma 6Carcinoma, Squamous Cell 6Astrocytoma 6Urinary Bladder Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Oropharyngeal Neoplasms 4Medulloblastoma 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bladder Urothelial Carcinoma × Radiation × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡